Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants

Fig. 1

Enrollment of patients with concomitant non-vlavular atrial fibrillation (AF) and diabetes mellitus (DM). From June 1, 2012, to December 31, 2017, a total of 3249 (16%), 6531 (31%), 1389 (6%), and 9798 (47%) non-valvular AF patients comorbid with DM taking apixaban, dabigatran, edoxaban, and rivaroxaban and 5812 consecutive patients taking warfarin were enrolled in the present study. Abbreviations: AF atrial fibrillation, DM diabetes mellitus, NOAC non-vitamin K antagonist oral anticoagulant, OAC oral anticoagulant

Back to article page